HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anju Ghangurde

Executive Editor, APAC

Mumbai, India

Anju has been a journalist since 1993 including stints at India's leading financial dailies. She covers a range of topics across the pharma and biosimilar landscape. Drug pricing, policy and regulatory affairs, M&A and patents are areas of special interest to her. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.

Latest From Anju Ghangurde

Glenmark Divests API Company, Setting Out On Distinct Journeys

Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”

Commercial M & A

Glenmark Divests API Company, Setting Out On Distinct Journeys

Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”

Commercial M & A

Sun Backs India-First Stroke Drug From Pharmazz

Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial.  The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.

Commercial India

India M&A Hourglass: Control Deals, ‘FOMO’, Monetization Calls At Family-Owned Firms

The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.

Commercial M & A

More Interest In Speculated Cipla Stake Sale: Portfolio, Cultural Fit Will Matter

After PEs, Torrent Pharma is speculated to be in the fray for a stake in Cipla. Experts weigh in on the contours of the product and cultural alignment of the two firms, should things move forward and also whether other Indian players could take a shot at the 'once in a lifetime opportunity'.

Deals M & A

Dr Reddy’s MD On The Next Horizon, Owner-Managed Firms, 'Birds And Beliefs'

Dr Reddy's Laboratories' co-chairman and MD, GV Prasad, talks about his conversations with late founder Dr Anji Reddy, the company’s ‘Horizon 2’ strategy, pricing expectations for CAR-T cell therapies, the promise of the China market, how Indian owner-managed pharma firms are figuring out ways to deal with succession aspects and his new book.

Commercial Strategy
See All
UsernamePublicRestriction

Register